Shares of Johnson & Johnson (NYSE:JNJ) ended Tuesday session in green amid volatile trading. The shares closed up +1.44 points or 1.22% at $119.22 with 5.35 million shares getting traded. Post opening the session at $118.39, the shares hit an intraday low of $117.72 and an intraday high of $119.22 and the price vacillated in this range throughout the day. The company has a market cap of $324.40 billion and the numbers of outstanding shares have been calculated to be 2.74 billion shares.
Johnson & Johnson (JNJ) on Sept. 20, 2016 announced a new five-year commitment to help advance the United Nations Sustainable Development Goals to help improve the health and well-being of men, women and children around the world. Johnson & Johnson is dedicating its expertise and innovations to ignite global partnerships and catalyze efforts through a variety of new implementation plans, targets and metrics. The announcement comes along with an expanded commitment by Johnson & Johnson to further strengthen the resilience of refugee and displaced children and their families in Syria and its neighboring countries where the need is greatest.
“Johnson & Johnson is committed to creating greater access to quality health care across the globe,” said Johnson & Johnson Chairman and CEO Alex Gorsky. “Beyond developing medicines, equipment and vaccines, we’re in communities helping expectant mothers take better care of themselves and their babies during pregnancy. We’re training nurses and doctors to identify and treat diseases, and also funding medical research. We’re proud to take a leading role with the world community in this effort, which will go a long way toward creating a healthier society.”
PLEDGE TO SUSTAINABLE DEVELOPMENT GOALS
Johnson & Johnson announced its pledge of support of the United Nations 2030 Sustainable Development Goals at an event hosted Monday in conjunction with the United Nations General Assembly in New York entitled “A Roadmap to Advance Human Health.” Johnson & Johnson convened more than 150 key thought leaders in global health and development to explore the importance of an integrated, multi-sector approach to improve the course of human health.
This commitment to advance the Sustainable Development Goals focuses on five key areas where Johnson & Johnson can optimize its diverse expertise, capabilities, collaborations and resources to make scalable and sustainable impact in promotion and advancement of the health workforce, women’s and children’s health, ensuring access to essential surgeries, environmental health and global disease challenges.
Shares of StemCells Inc (NASDAQ:STEM) ended Tuesday session in red amid volatile trading. The shares closed down -0.01 points or -0.71% at $1.40 with 248,416.00 shares getting traded. Post opening the session at $1.40, the shares hit an intraday low of $1.39 and an intraday high of $1.42 and the price vacillated in this range throughout the day. The company has a market cap of $17.17 million and the numbers of outstanding shares have been calculated to be 12.01 million shares.
StemCells Inc (STEM) engages in the research, development, and commercialization of cell-based therapeutics and related technologies. It develops HuCNS-SC platform technology, a purified human neural stem cells used as a potential therapeutic to treat diseases and disorders of the central nervous system. The companys HuCNS-SC is in Phase I clinical trials for the treatment of Pelizeaus-Merzbacher Disease; and has completed a Phase I clinical trial for infantile and late infantile neuronal ceroid lipofuscinosis. Its HuCNS-SC is also in Phase I/II clinical trials for the treatment of thoracic spinal cord injury; Phase II clinical trials for the treatment of cervical spinal cord injury; and Phase I/II clinical trials for dry age-related macular degeneration. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.